Aducanumab

• CAT Number: I043751
• CAS Number: 1384260-65-4
• Purity: ≥95%

Aducanumab (BIIB037) is a human monoclonal antibody that selectively targets aggregated amyloid-beta (Aβ). Aducanumab shows brain penetration, and can be used for Alzheimer’s disease (AD) research[1].
Aducanumab (30 mg/kg, i.p., single dose) binds all morphological types of brain Aβ plaques in 22-month-old Tg2576 transgenic mice, including diffuse Aβ deposits and compact Aβ plaques[1].
Aducanumab (0.3-30 mg/kg, i.p., weekly, 6 months) reduces soluble and insoluble Aβ in a dose-dependent manner in 9.5- to 15.5-month-old Tg2576 transgenic mice[1].
Aducanumab (10 mg/kg, i.p., weekly, 6 months) restores intracellular calcium to control levels in 18-month-old Tg2576 mice[2].
Aducanumab (0.4-1 mg/mL, ICV, 20 min) leads to rapid decrease in amyloid burden, plaque clearance in Tg2576 mice[2].

Reference

[1]. Sevigny J, et al. The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease. Nature. 2016 Sep 1;537(7618):50-6.
 [Content Brief]

[2]. Kastanenka KV, et al. Immunotherapy with Aducanumab Restores Calcium Homeostasis in Tg2576 Mice. J Neurosci. 2016 Dec 14;36(50):12549-12558.
 [Content Brief]